Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02219516 · ClinicalTrials.gov registry record · Phase 1
Mild, Moderate and Severe Renal Impairment Study
A Phase 1 study of Gout, sponsored by Ardea Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
- 4
- Study locations
NCT02219516: Completed Phase 1 study of Gout, sponsored by Ardea Biosciences.
NCT02219516 is a Phase 1 study of Gout that has completed, run by Ardea Biosciences. The registered enrollment target is 31 participants, below the 8,887-participant average among 34 other Gout trials with a reported enrollment target (100% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02219516, a Phase 1 study of Gout, has completed, sponsored by Ardea Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a Phase 1, single-dose, open-label, pharmacokinetic (PK) and pharmacodynamic (PD) study of RDEA3170 in adult male subjects with mild, moderate, and severe renal impairment.
Primary Outcome
Cmax following a single administration of RDEA3170 to subjects with various degrees of renal function
Conditions Studied
Interventions
- DRUG RDEA3170
Study Locations (4)
Colorado
- - Lakewood
Florida
- - Orlando
Minnesota
- - Minneapolis
Tennessee
- - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2014-08-01 |
| Est. Completion | 2016-05-13 |
| Phase | Phase 1 |
What the finished NCT02219516 record still lists
NCT02219516 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 8,887-participant average among 34 other Gout trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Gout appearing as the primary indexed condition, and to 1 intervention - of which RDEA3170 is the first listed.
NCT02219516 reports a single indexed study location in Colorado, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT02219516 about?
NCT02219516 is a clinical study titled "Mild, Moderate and Severe Renal Impairment Study". This is a Phase 1, single-dose, open-label, pharmacokinetic (PK) and pharmacodynamic (PD) study of RDEA3170 in adult male subjects with mild, moderate, and severe renal impairment.
What is the current status of trial NCT02219516?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2014-08-01. Estimated completion is 2016-05-13.
What conditions does trial NCT02219516 study?
This clinical trial studies the following conditions: Gout.
What interventions are being tested in trial NCT02219516?
The interventions under investigation include: RDEA3170 (DRUG).
Who is sponsoring clinical trial NCT02219516?
This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02219516 being conducted?
This trial has 4 study locations across Colorado, Florida, Minnesota, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gout
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02219516's enrollment target sits among peer trials
31 24th of 34 higher than 11 of 34 other Gout trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gout trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Pharmacodynamics of SEL-037 (Pegsiticase) in Subjects With Elevated Blood Uric Acid Levels
COMPLETED · Phase 1
-
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia
COMPLETED · Phase 1
-
The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults.
COMPLETED · Phase 1
-
NSAID Drug Interaction Study
COMPLETED · Phase 1
-
Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI